Denileukine Diftitox for Relapsed ALCL

Inclusion Criteria: * Age: Patients must be ≥ 2.00 year and ≤ 24.99 years of age at the time of study entry. * Diagnosis: Patients must have previous histologic verification of anaplastic large cell lymphoma (ALCL). Patients must be in first, second or third relapse or initial induction failure. \- Disease Status: Patients must have measurable radiographic disease. \- Performance Level: Karnofsky \> 60% for patients \> 16 years of age and Lansky \> 60 for patients \<16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. \- Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. Patients who are post-allogeneic transplant should be off immunosuppressive agents prior to starting therapy. Steroid doses should also be stable or decreasing for at least 1 week prior to starting therapy. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (6 weeks if prior nitrosourea). Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. These patients must be discussed with the Study Chair on a case-by-case basis. XRT: \> 2 wks for local palliative XRT (small port); \> 2 months must have elapsed if prior TBI, craniospinal XRT or if \> 50% radiation of pelvis; \> 6 wks must have elapsed if other substantial BM radiation. Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and \> 2 months must have elapsed since SCT. Patients may not have received prior therapy with Denileukin Diftitox \- Organ Function Requirements Adequate Bone Marrow Function Defined As: 1. For patients without bone marrow involvement: * Peripheral absolute neutrophil count (ANC) \> 1,000 * Platelet count \> 100,000 (transfusion independent) * Hemoglobin \> 8.0 gm (RBC transfusion independent) 2. For patients with bone marrow involvement: * Peripheral absolute neutrophil count (ANC) \> 1,0 * Platelet count \> 20,000 (may receive platelet transfusions) * Hemoglobin \> 8.0 (may receive RBC transfusions) Adequate Renal Function Defined As: Creatinine clearance or radioisotope GFR 70mL/min/1.73m2 OR A serum/plasma creatinine GFR calculation using the Schwartz formula (Schwartz et al. J. Peds, 106:522, 1985) Estimated Creatinine Clearance (in mL/min/1.73 m2) = (k)(L)/Pcr Where L = child's length in cm Pcr = plasma (or serum) creatinine (in mg/dL) k Values = 0.33 low birth weight infant 0.45 term infant 0.55 child 0.55 adolescent female 0.70 adolescent male Adequate Liver Function Defined As: * Bilirubin (sum of conjugated + unconjugated) \< 1.5 x upper limit of normal (ULN) for age, and * SGPT (ALT) \< 3 x upper limit of normal (ULN) for age * Serum albumin \> 2 g/dL. Exclusion Criteria: * Patients must not be currently receiving another investigational drug. * Patients must not be currently receiving other anti-cancer agents. * Patients must have a negative pregnancy test and Nursing mothers must agree not to breast-feed. * Patients who have a documented uncontrolled infection requiring IV antibiotics * Patients with CNS disease are not eligible.